Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.

Duvakitug significantly improved clinical remission rates in patients with moderate to severe ulcerative colitis, with response rates of up to 48% at week 14.

• Why it matters: Ulcerative colitis is a chronic condition with limited effective treatments, especially for patients who do not respond to conventional therapies, highlighting the need for new options.
• What they did: A phase 2b, randomized, placebo-controlled trial tested two doses of duvakitug (450 mg and 900 mg) in 137 adults, assessing clinical remission at week 14 using Bayesian analysis.
• The result: The 900 mg dose achieved a response rate of 48%, with high probability of superiority over placebo, and safety profiles were comparable, supporting duvakitug's potential as a treatment option.